Tyrosine kinase inhibitors-ZD1839 (Iressa).

Abstract:

:Several epithelial tumors display epidermal growth factor receptor (EGFR) overexpression (with or without EGFR gene amplification) that is often associated with increased production of EGFR ligands. This permits the activation of endogenous tumor EGFR via autocrine mechanisms, resulting in cellular proliferation and tumor growth. Interruption of receptor signaling with bivalent EGFR antibodies or with small molecule inhibitors of the EGFR tyrosine kinase results in inhibition of tumor cell proliferation or viability in vitro and in vivo. One small molecule currently undergoing preclinical and clinical investigation is ZD1839 (Iressa), a synthetic anilinoquinazoline capable of inhibiting EGFR tyrosine kinase in vitro. The early results of clinical trials indicate this drug possesses antitumor activity in certain malignancies of the upper aerodigestive tract.

journal_name

Curr Opin Oncol

authors

Arteaga CL,Johnson DH

doi

10.1097/00001622-200111000-00012

keywords:

subject

Has Abstract

pub_date

2001-11-01 00:00:00

pages

491-8

issue

6

eissn

1040-8746

issn

1531-703X

journal_volume

13

pub_type

杂志文章,评审
  • High-dose therapy with autologous bone marrow transplantation for the treatment of solid tumors.

    abstract::Over the past decade, high-dose chemotherapy followed by autologous bone marrow support (ABMS) has been employed with increasing frequency to treat patients with a variety of solid tumors. This paper explores the rationale and relevant clinical data for the use of this approach to treat patients with breast and ovaria...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-199403000-00004

    authors: Shpall EJ,Jones RB,Bearman S

    更新日期:1994-03-01 00:00:00

  • Primary thyroid lymphoma: a review of recent developments in diagnosis and histology-driven treatment.

    abstract:PURPOSE OF REVIEW:Primary thyroid lymphoma (PTL) is a rare but clinically important malignancy of the thyroid. This article reviews the diagnosis, histologic subtypes, pathogenesis, and treatment of PTL, with the objective of optimizing diagnosis and management of the disease. RECENT FINDINGS:Recent studies have shed ...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e3283330848

    authors: Graff-Baker A,Sosa JA,Roman SA

    更新日期:2010-01-01 00:00:00

  • Molecular genetic markers as predictors of response to chemotherapy in gliomas.

    abstract:PURPOSE OF REVIEW:This review summarizes recent studies on applications of molecular markers such as chromosome 1p/19q codeletion and MGMT status in the treatment of glioma. RECENT FINDINGS:Prospective trials confirmed that 1p/19q codeletion represents a strong and independent favourable prognostic factor in anaplasti...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e3282f075f3

    authors: Idbaih A,Omuro A,Ducray F,Hoang-Xuan K

    更新日期:2007-11-01 00:00:00

  • Pediatric genitourinary tumors.

    abstract:PURPOSE OF REVIEW:To review the 2008-2009 literature on pediatric genitourinary tumors and highlight the most significant publications. RECENT FINDINGS:New techniques such as gene expression profiling, PET, nephron-sparing surgery, and stem cell transplantation are being incorporated into contemporary treatments for p...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e32833841a1

    authors: McLean TW,Buckley KS

    更新日期:2010-05-01 00:00:00

  • Myelodysplastic syndromes in children.

    abstract:PURPOSE OF REVIEW:Myelodysplastic syndromes (MDSs) are rare disorders in children, showing peculiar clinical manifestations and biological features. This review will summarize biological, genetic and clinical features of childhood MDS and will provide an update of the algorithm of treatment of the different disease var...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000488

    authors: Galaverna F,Ruggeri A,Locatelli F

    更新日期:2018-11-01 00:00:00

  • Adult desmoid tumors: biology, management and ongoing trials.

    abstract:PURPOSE OF REVIEW:To summarize the current knowledge about the biology and clinical management of adult desmoid tumors. RECENT FINDINGS:In the past decade, we have learned that desmoid tumors are driven by alterations of the Wnt/APC/β-catenin pathway, sporadic desmoid tumors are associated with somatic mutations of CT...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000374

    authors: Penel N,Chibon F,Salas S

    更新日期:2017-07-01 00:00:00

  • Tumor microenvironment in mycosis fungoides and Sézary syndrome.

    abstract:PURPOSE OF REVIEW:Mycosis fungoides and Sézary syndrome arise from malignant T cells that reside in skin, and subsequently are capable of circulating between skin, lymph nodes, and blood. The pathophysiologic mechanisms that cause and result in different behaviors of the skin-homing-malignant T cells in different stage...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000243

    authors: Rubio Gonzalez B,Zain J,Rosen ST,Querfeld C

    更新日期:2016-01-01 00:00:00

  • State-of-the-art in the management of locally advanced and metastatic gallbladder cancer.

    abstract:PURPOSE OF REVIEW:Gallbladder carcinoma (GBC), classified as a biliary tract cancer (BTC) along with intrahepatic and extrahepatic cholangiocarcinomas, is a rare disease in Western countries, but a highly prevalent disease in Chile, other countries in Latin America, India and Japan. It commonly presents at an advanced ...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e3283620fd8

    authors: McNamara MG,Metran-Nascente C,Knox JJ

    更新日期:2013-07-01 00:00:00

  • New drug therapy for squamous carcinoma of the head and neck.

    abstract::The identification of new active agents for the treatment of squamous carcinoma of the head and neck remains a high priority for clinical investigators. For the past several years a number of investigational drugs have demonstrated activity in patients with recurrent or metastatic disease. Included are the following a...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-199605000-00009

    authors: Murphy BA

    更新日期:1996-05-01 00:00:00

  • Update in germ cell tumours.

    abstract:PURPOSE OF REVIEW:The purpose of this study is to update the reader on advances in postpubertal male germ cell tumours (GCTs) over the last 18 months. RECENT FINDINGS:Single nucleotide polymorphisms, including in four sex-determination genes, have been identified as additional genetic susceptibility loci to testicular...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000179

    authors: Feldman DR

    更新日期:2015-05-01 00:00:00

  • Treatment of AIDS-related lymphomas.

    abstract::Infection with HIV is associated with an increased risk of systemic and primary central nervous system non-Hodgkin's lymphoma. Patients with systemic non-Hodgkin's lymphoma usually present with high- or intermediate-grade histology and extranodal dissemination. Although the prognosis for such patients is poor, some pa...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sparano JA

    更新日期:1995-09-01 00:00:00

  • p53, stem cell biology and childhood blastomas.

    abstract:PURPOSE OF REVIEW:Childhood blastomas, unlike adult cancers, originate from developing organs in which molecular and cellular features exhibit differentiation arrest and embryonic characteristics. Conventional cancer therapies, which rely on the generalized cytotoxic effect on rapidly dividing cells, may damage delicat...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000504

    authors: Oh L,Hafsi H,Hainaut P,Ariffin H

    更新日期:2019-03-01 00:00:00

  • Pralatrexate: an emerging new agent with activity in T-cell lymphomas.

    abstract:PURPOSE OF REVIEW:T-cell lymphomas (TCL) represent a particularly poor prognosis subgroup of lymphomas. The goal of this review is to provide emerging information on one agent demonstrating activity in these challenging diseases. Pralatrexate is a novel antifolate designed to have high affinity for the reduced folate c...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/01.cco.0000245309.74767.20

    authors: O'Connor OA

    更新日期:2006-11-01 00:00:00

  • Brain metastases: current management and new developments.

    abstract:PURPOSE OF REVIEW:To review the state-of-the-art and new developments in the management of patients with brain metastases. RECENT FINDINGS:Treatment decisions are based on prognostic factors to maximize neurologic function and survival, while avoiding unnecessary therapies. Whole-brain radiotherapy (WBRT) is the treat...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e32831186fe

    authors: Soffietti R,Rudà R,Trevisan E

    更新日期:2008-11-01 00:00:00

  • Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer.

    abstract::Tyrosine kinase (type 1) growth factor receptors include the erbB family. These cell surface receptors were discovered in the context of cellular transformation and have subsequently been found to be overexpressed in many types of human cancer. Cumulative evidence suggests that upregulation of the most well-characteri...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-200105000-00007

    authors: Lango MN,Shin DM,Grandis JR

    更新日期:2001-05-01 00:00:00

  • Elderly patients with multiple myeloma: towards a frailty approach?

    abstract:PURPOSE OF REVIEW:To describe how to better identify frail multiple myeloma patients and to treat them appropriately. RECENT FINDINGS:Proteasome inhibitors, such as bortezomib, carfilzomib, and ixazomib, and immunomodulatory agents (IMiDs), such as thalidomide, lenalidomide, and pomalidomide, have significantly improv...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000395

    authors: Zweegman S,Engelhardt M,Larocca A,EHA SWG on ‘Aging and Hematology’.

    更新日期:2017-09-01 00:00:00

  • Management of women at risk for malignancy.

    abstract::Family history plays an important role in breast, ovarian, and colorectal cancers. The increasing availability of genetic testing has forced women with these malignancies and their physicians to confront new questions regarding screening and prevention. This review highlights the screening for and prevention of breast...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-200009000-00019

    authors: Basil JB,Rader JS

    更新日期:2000-09-01 00:00:00

  • Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?

    abstract:PURPOSE OF REVIEW:Prevention of infectious complications of chemotherapy-induced granulocytopenia is a major issue in preventive medicine, as febrile neutropenia is still associated with an overall 10% mortality and extensive morbidity and cost. RECENT FINDINGS:The prescription of granulocyte colony-stimulating factor...

    journal_title:Current opinion in oncology

    pub_type: 社论,评审

    doi:10.1097/CCO.0b013e32832c9651

    authors: Klastersky J,Awada A,Aoun M,Paesmans M

    更新日期:2009-07-01 00:00:00

  • Retinoids.

    abstract::This review highlights recent advances in understanding the mode of action of retinoids at the level of molecular and cellular biology in relation to the new clinical results achieved with retinoids in various malignancies. All-trans-retinoic acid has been established in the clinic as a first-line differentiation ther...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-199311000-00019

    authors: Holdener EE,Bollag W

    更新日期:1993-11-01 00:00:00

  • Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects.

    abstract:PURPOSE OF REVIEW:Temsirolimus (Torisel) is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). The recommended dosage in this indication (175 mg once weekly for 3 weeks and then 75 mg once weekly as maintenance) is higher than that for renal ce...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e32835de8ee

    authors: Bouabdallah K,Ribrag V,Terriou L,Soria JC,Delarue R

    更新日期:2013-03-01 00:00:00

  • Environmental estrogens and breast cancer risk.

    abstract::Controversy exists over the role that environmental estrogens, such as pesticides or polychlorinated biphenyls (PCBs), might play as risk factors for breast cancer. Several laboratory studies have suggested that these chemicals function as weak estrogens, binding to the estrogen receptor and inducing various measures ...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-199809000-00018

    authors: Davidson NE

    更新日期:1998-09-01 00:00:00

  • Recent developments and controversies in primary central nervous system lymphoma.

    abstract:PURPOSE OF REVIEW:Primary central nervous system lymphoma (PCNSL) is a rare tumor, and its optimal management is a matter of controversy. Recent developments of collaborative groups devoted to PCNSL have allowed to conduct randomized trials addressing important issues. In addition, genome wide analysis provided new ins...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000233

    authors: Hottinger AF,Alentorn A,Hoang-Xuan K

    更新日期:2015-11-01 00:00:00

  • What is new in the management of salivary gland cancers?

    abstract:PURPOSE OF REVIEW:Salivary gland malignancies are a rare and heterogeneous group of tumors with considerable variability in their natural history. Historically they have been treated with surgery and radiation therapy. It is only recently that there has been any growth in our understanding of these diseases and their m...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e328344f59c

    authors: Adelstein DJ,Rodriguez CP

    更新日期:2011-05-01 00:00:00

  • Recent advances in breast cancer biology.

    abstract::Approximately 1 in 10 US women will be diagnosed with breast cancer in her lifetime. With such a high incidence, breast cancer is a serious health concern for all American women. Within the past year, clues about the function of genes associated with breast cancer have been garnered, and novel genes that may contribut...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-200011000-00002

    authors: Unger MA,Weber BL

    更新日期:2000-11-01 00:00:00

  • Bcl-2 antisense therapy in hematologic malignancies.

    abstract:PURPOSE OF REVIEW:Overexpression of the Bcl-2 oncoprotein is noted in various malignant disorders. In patients with hematologic malignancies, increased production of the Bcl-2 oncoprotein is associated with chemotherapy resistance, aggressive clinical course, and poor survival. Bcl-2 is an important molecular target. D...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/01.cco.0000142074.67968.eb

    authors: Chanan-Khan A

    更新日期:2004-11-01 00:00:00

  • Update in Kaposi sarcoma.

    abstract:PURPOSE OF REVIEW:Knowledge of the pathophysiology of Kaposi sarcoma continues to expand and influence our therapeutic approaches. This review summarizes developments within the last 18 to 24 months. RECENT FINDINGS:Pieces of the puzzle as they relate to viral factors-both human herpes virus 8 (HHV-8) and human immuno...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-200309000-00006

    authors: Noy A

    更新日期:2003-09-01 00:00:00

  • Three molecular determinants of malignant conversion and their potential as therapeutic targets.

    abstract::The past decade has been marked by an explosion of knowledge regarding the dysregulation of cancer at the molecular level. It has become apparent that oncogenes, tumor suppressor genes, and other ancillary molecules interact in complex pathways that govern cellular homeostasis. We review three molecular events that ha...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-199901000-00013

    authors: Dome JS,Look AT

    更新日期:1999-01-01 00:00:00

  • Clear cell cancer of the ovary.

    abstract:PURPOSE OF REVIEW:Recent discoveries have demonstrated that ovarian cancer is actually composed of multiple separate diseases. Clear cell cancer is an important example. This review will describe the unique biology of clear cell carcinoma, its novel molecular features, and the recent translation of this into new therap...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e328363e0c7

    authors: Penson RT,Dizon DS,Birrer MJ

    更新日期:2013-09-01 00:00:00

  • Clinical application of molecular pathology in sarcomas.

    abstract:PURPOSE OF REVIEW:This review is intended to highlight the clinical application of molecular pathology as a tool for diagnostic accuracy and prognostic and predictive use and finally to discover novel molecular therapeutic targets. RECENT FINDINGS:We are living an exciting era in sarcomas' therapy. This is the result ...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e328347b9be

    authors: Romeo S,Dei Tos AP

    更新日期:2011-07-01 00:00:00

  • Bevacizumab in the treatment of metastatic breast cancer: three case reports.

    abstract::Case reports are presented for three patients with metastatic breast cancer who received first-line treatment with bevacizumab in combination with taxanes in clinical trials. Two patients showed peak reductions in lesion size of 49 and 70%, respectively. In one patient, subsequent treatment with bevacizumab in combina...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章

    doi:10.1097/01.cco.0000397418.52374.28

    authors: Ferreira A,Vieira C,Rodrigues A,Pereira D,Rodrigues H,Dávila C,Bento S

    更新日期:2011-04-01 00:00:00